scholarly article | Q13442814 |
review article | Q7318358 |
P50 | author | Ralph A. DeFronzo | Q58689309 |
P2093 | author name string | M. Abdul-Ghani | |
P2860 | cites work | Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 |
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial | Q24656644 | ||
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 | ||
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance | Q28186874 | ||
Impaired fasting glucose and impaired glucose tolerance: implications for care | Q28290479 | ||
Thirty-one novel biomarkers as predictors for clinically incident diabetes | Q28752614 | ||
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study | Q29615122 | ||
10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes | Q29619192 | ||
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development | Q31979634 | ||
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial | Q33425402 | ||
Plasma glucose concentration and prediction of future risk of type 2 diabetes | Q33610774 | ||
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. | Q33864120 | ||
Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009 | Q33880303 | ||
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial | Q33999757 | ||
Lifestyle intervention for prevention of type 2 diabetes in primary health care: one-year follow-up of the Finnish National Diabetes Prevention Program (FIN-D2D). | Q34153413 | ||
Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program | Q34312885 | ||
Thiazolidinediones | Q34346862 | ||
Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes. | Q34363859 | ||
The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes | Q34655580 | ||
Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. | Q36369954 | ||
Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose | Q36462545 | ||
The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program | Q36496751 | ||
One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes | Q36807453 | ||
Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies | Q36839519 | ||
First versus repeat treatment with a lifestyle intervention program: attendance and weight loss outcomes | Q36952995 | ||
Economic costs of diabetes in the U.S. In 2007. | Q37097601 | ||
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial | Q37151277 | ||
Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort | Q37235925 | ||
Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change | Q37312881 | ||
Skeletal muscle insulin resistance is the primary defect in type 2 diabetes | Q37624257 | ||
Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease | Q37742798 | ||
Role of glycated hemoglobin in the prediction of future risk of T2DM. | Q39742092 | ||
Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance | Q40964485 | ||
A two-step model for development of non-insulin-dependent diabetes | Q41178482 | ||
Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study | Q42982910 | ||
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study | Q43255700 | ||
Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study | Q43959543 | ||
Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women | Q44114894 | ||
beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis | Q45105931 | ||
Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. | Q46036413 | ||
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years | Q46870991 | ||
The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). | Q46878587 | ||
Prevalence of polyneuropathy in pre-diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. | Q46881268 | ||
Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study | Q50546299 | ||
Predicting diabetes. Moving beyond impaired glucose tolerance. | Q51056294 | ||
Pioglitazone for diabetes prevention in impaired glucose tolerance. | Q51161029 | ||
Thiazolidinediones improve beta-cell function in type 2 diabetic patients. | Q51485541 | ||
Risk of progression to type 2 diabetes based on relationship between postload plasma glucose and fasting plasma glucose. | Q51495723 | ||
The metabolic profile of NIDDM is fully established in glucose-tolerant offspring of two Mexican-American NIDDM parents | Q51603248 | ||
The natural history of impaired glucose tolerance in the Pima Indians. | Q51623599 | ||
Diabetes incidence in Pima indians: contributions of obesity and parental diabetes | Q71499753 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivatives | Q6937225 |
P407 | language of work or name | English | Q1860 |
P921 | main subject | pharmacology | Q128406 |
anti-diabetic medication | Q575062 | ||
type 2 diabetes | Q3025883 | ||
P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
P304 | page(s) | S202-9 | |
P577 | publication date | 2011-05-01 | |
P1433 | published in | Diabetes Care | Q5270111 |
P1476 | title | Type 2 diabetes can be prevented with early pharmacological intervention | |
P478 | volume | 34 Suppl 2 |
Q91841793 | A gene expression network analysis of the pancreatic islets from lean and obese mice identifies complement 1q like-3 secreted protein as a regulator of β-cell function |
Q33998049 | Addressing prediabetes in childhood obesity treatment programs: support from research and current practice |
Q34327998 | Allele summation of diabetes risk genes predicts impaired glucose tolerance in female and obese individuals |
Q49267983 | Beneficial Effect of Bis(Hinokitiolato)Zn Complex on High-fat Diet-induced Lipid Accumulation in Mouse Liver and Kidney |
Q35548033 | Beneficial effects of canagliflozin in combination with pioglitazone on insulin sensitivity in rodent models of obese type 2 diabetes |
Q38727328 | Beyond the Protein-Coding Sequence: Noncoding RNAs in the Pathogenesis of Type 2 Diabetes |
Q51324810 | Clinical study of exercise on improvement of β-cell function and insulin resistance in non-diabetic young offsprings of diabetic patients. |
Q38628118 | Combination therapy of an intestine-specific inhibitor of microsomal triglyceride transfer protein and peroxisome proliferator-activated receptor γ agonist in diabetic rat |
Q26741860 | Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice |
Q33750414 | Continuous glucose monitoring system and new era of early diagnosis of diabetes in high risk groups. |
Q26830284 | Diabetic complications in obese type 2 diabetic rat models |
Q40012754 | Difference in postprandial GLP-1 response despite similar glucose kinetics after consumption of wheat breads with different particle size in healthy men. |
Q48300528 | Different intervention strategies for preventing type 2 diabetes mellitus in China: A systematic review and network meta-analysis of randomized controlled trials. |
Q36207857 | Does prediabetes cause small fiber sensory polyneuropathy? Does it matter? |
Q49343374 | Effects on Glycemic Control in Impaired Wound Healing in Spontaneously Diabetic Torii (SDT) Fatty Rats. |
Q35646093 | Enhanced fatty acid flux triggered by adiponectin overexpression |
Q57477787 | Five-year effectiveness of short messaging service (SMS) for pre-diabetes |
Q47929211 | High normal HbA(1c) levels were associated with impaired insulin secretion without escalating insulin resistance in Japanese individuals: the Toranomon Hospital Health Management Center Study 8 (TOPICS 8). |
Q35645142 | Hormesis does not make sense except in the light of TOR-driven aging |
Q38765909 | Hypothalamic Insulin Resistance in Obesity: Effects on Glucose Homeostasis |
Q28488095 | Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)--relationship to newly identified mitochondrial pyruvate carrier proteins |
Q36035534 | Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts. |
Q37449520 | Incidental findings of elevated random plasma glucose in the ED as a prompt for outpatient diabetes screening: a retrospective study |
Q35014728 | Inclusion of plasma lipid species improves classification of individuals at risk of type 2 diabetes |
Q47568764 | Incorporation of suboptimal health status as a potential risk assessment for type II diabetes mellitus: a case-control study in a Ghanaian population |
Q41553095 | Long Noncoding RNAs as Diagnostic and Therapeutic Targets in Type 2 Diabetes and Related Complications |
Q37721470 | Mechanistic Insight and Management of Diabetic Nephropathy: Recent Progress and Future Perspective. |
Q30238940 | Medical Management of Diabesity: Do We Have Realistic Targets? |
Q38096980 | Metabolic Surgery for Type 2 Diabetes in Patients with a BMI of <35 kg/m(2): A Surgeon's Perspective |
Q38936275 | Metabolic alterations, HFE gene mutations and atherogenic lipoprotein modifications in patients with primary iron overload. |
Q33469871 | Mulberry-extract improves glucose tolerance and decreases insulin concentrations in normoglycaemic adults: Results of a randomised double-blind placebo-controlled study |
Q35983091 | Naturally improving insulin resistance with amorfrutins |
Q35221336 | Novel views on new-onset diabetes after transplantation: development, prevention and treatment. |
Q34688748 | Overview of insulin and non-insulin delivery devices in the treatment of diabetes |
Q47901833 | Pharmacodynamic Effects of Low-Dose Pioglitazone in Patients with the Metabolic Syndrome without Diabetes Mellitus |
Q40965150 | Pioglitazone improves whole-body aerobic capacity and skeletal muscle energy metabolism in patients with metabolic syndrome |
Q60310073 | Prevention of type 2 diabetes mellitus with acupuncture: Protocol for a systematic review and meta-analysis |
Q41636583 | Profiling of cardio-metabolic risk factors and medication utilisation among Type II diabetes patients in Ghana: a prospective cohort study |
Q34498840 | Profound defects in β-cell function in screen-detected type 2 diabetes are not improved with glucose-lowering treatment in the Early Diabetes Intervention Program (EDIP). |
Q35825694 | Proximal correlates of metabolic phenotypes during 'at-risk' and 'case' stages of the metabolic disease continuum |
Q39025151 | Retinol binding protein-4 predicts incident diabetes in Asian Indian men with prediabetes |
Q52579262 | Semen Cassiae Extract Improves Glucose Metabolism by Promoting GlUT4 Translocation in the Skeletal Muscle of Diabetic Rats. |
Q38610829 | The TZD insulin sensitizer clue provides a new route into diabetes drug discovery |
Q27014777 | The association of periodontitis and metabolic syndrome |
Q26825074 | The reality of type 2 diabetes prevention |
Q45825323 | Type 2 diabetes in Asia: like chronic obstructive pulmonary disease, a threat to human health and wellbeing |
Q93178009 | Understanding the growing epidemic of type 2 diabetes in the Hispanic population living in the United States |
Q30392979 | Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum |
Q36477239 | Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. |
Q35209811 | Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials |
Q83568914 | [Benefits and risks of current pharmacotherapy in the treatment of type 2 diabetes] |